drugset / Trial / NCT04433221
Combination Immunotherapy Targeting Sarcomas
NaSingle-groupOpen-labelTreatment
Summary
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2029-05-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Multiple sarcoma-specific CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Multiple sarcoma-specific CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |